{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:27:24Z","timestamp":1794378444279,"version":"4.9.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:p>\n                    The pathogenesis and clinicopathological features of hepatocellular carcinoma (HCC) harboring\n                    <jats:italic toggle=\"yes\">JAK1<\/jats:italic>\n                    mutation have not been reported. Sixty inflammatory hepatocellular adenoma-like HCCs (IHA-like HCCs) and 16 IHAs were analyzed using targeted next-generation sequencing. Nearly all IHA-like HCCs (n=59, 98%) showed positive SAA\/CRP expression. Genetic alterations of the JAK\/STAT pathway were detected in 35 (58%) IHA-like HCCs, encompassing mutations in\n                    <jats:italic toggle=\"yes\">JAK1<\/jats:italic>\n                    (n=22),\n                    <jats:italic toggle=\"yes\">STAT3<\/jats:italic>\n                    (n=8), and\n                    <jats:italic toggle=\"yes\">IL6ST<\/jats:italic>\n                    (n=5). Nine (56%) IHAs harbored mutations in\n                    <jats:italic toggle=\"yes\">STAT3<\/jats:italic>\n                    (n=3),\n                    <jats:italic toggle=\"yes\">IL6ST<\/jats:italic>\n                    (n=4),\n                    <jats:italic toggle=\"yes\">GNAS<\/jats:italic>\n                    (n=1), and\n                    <jats:italic toggle=\"yes\">FRK<\/jats:italic>\n                    (n=1). All the mutations occurred in a mutually exclusive manner.\n                    <jats:italic toggle=\"yes\">JAK1<\/jats:italic>\n                    mutations were frequent (22\/60, 37%) in IHA-like HCCs.\n                    <jats:italic toggle=\"yes\">JAK1<\/jats:italic>\n                    -mutated IHA-like HCCs displayed distinctive cytologic characteristics, including abundant eosinophilic cytoplasm, vesicular chromatin, and prominent central nucleoli. Recurrent hotspot\n                    <jats:italic toggle=\"yes\">JAK1<\/jats:italic>\n                    mutations were identified at S703, S729, and L910. Surveillance for\n                    <jats:italic toggle=\"yes\">JAK1<\/jats:italic>\n                    mutations in the HCC genomics of other cohorts also revealed recurrent mutations at S703, S729, and L910. In particular, the S703 and S729 mutations were strongly associated with the features of Asian ethnicity, presence of chronic viral hepatitis, and hepatic fibrosis\/cirrhosis. In conclusion,\n                    <jats:italic toggle=\"yes\">JAK1<\/jats:italic>\n                    mutations were frequent in HCC with IHA-like morphology in an Asian cohort.\n                    <jats:italic toggle=\"yes\">JAK1<\/jats:italic>\n                    mutation exhibited recurrent and specific hotspot mutations at S703, S729, and L910 in HCC. Patients diagnosed with\n                    <jats:italic toggle=\"yes\">JAK1-<\/jats:italic>\n                    mutated HCC may be eligible for JAK-targeted molecular therapy.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000002619","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:00:13Z","timestamp":1789628413000},"page":"1498-1507","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Hepatocellular Carcinoma With JAK1 Mutations Harbors Distinct Histologic Features and Specific Mutational Hotspots in an Asian Cohort"],"prefix":"10.1097","volume":"50","author":[{"given":"Jia-Huei","family":"Tsai","sequence":"first","affiliation":[{"name":"Department of Pathology, National Taiwan University Hospital"},{"name":"Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Ming","family":"Jeng","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Taiwan University Hospital"},{"name":"Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Taiwan University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jau-Yu","family":"Liau","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Taiwan University Hospital"},{"name":"Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"R1-20261111","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/08977194.2012.660936","article-title":"Biology and significance of the JAK\/STAT signalling pathways","volume":"30","author":"Kiu","year":"2012","journal-title":"Growth Factors"},{"key":"R2-20261111","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cyto.2018.03.041","article-title":"The regulation of JAKs in cytokine signaling and its breakdown in disease","volume":"118","author":"Hammar\u00e9n","year":"2019","journal-title":"Cytokine"},{"key":"R3-20261111","doi-asserted-by":"crossref","first-page":"13764","DOI":"10.3390\/ijms241813764","article-title":"Exploring the JAK\/STAT signaling pathway in hepatocellular carcinoma: unraveling signaling complexity and therapeutic implications","volume":"24","author":"Park","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R4-20261111","doi-asserted-by":"crossref","first-page":"HEP18","DOI":"10.2217\/hep-2020-0001","article-title":"JAK\/STAT signaling in hepatocellular carcinoma","volume":"7","author":"Hin Tang","year":"2020","journal-title":"Hepat Oncol"},{"key":"R5-20261111","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3390\/cancers11111704","article-title":"Jak-Stat signaling induced by interleukin-6 family cytokines in hepatocellular carcinoma","volume":"11","author":"Lokau","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R6-20261111","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"Levine","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"R7-20261111","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/cancers13040800","article-title":"Janus kinases in leukemia","volume":"13","author":"Raivola","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R8-20261111","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1158\/1078-0432.CCR-07-4839","article-title":"Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers","volume":"14","author":"Jeong","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R10-20261111","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/hep.21743","article-title":"Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry","volume":"46","author":"Bioulac-Sage","year":"2007","journal-title":"Hepatology"},{"key":"R11-20261111","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/gutjnl-2019-319790","article-title":"Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK\/STAT pathway in inflammatory hepatocellular adenomas","volume":"69","author":"Bayard","year":"2020","journal-title":"Gut"},{"key":"R12-20261111","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/gut.2010.222109","article-title":"Changing trends in malignant transformation of hepatocellular adenoma","volume":"60","author":"Farges","year":"2011","journal-title":"Gut"},{"key":"R13-20261111","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.03.005","article-title":"Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation","volume":"25","author":"Pilati","year":"2014","journal-title":"Cancer Cell"},{"key":"R14-20261111","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/hep.28638","article-title":"Genotype-phenotype correlation of CTNNB1 mutations reveals different \u00df-catenin activity associated with liver tumor progression","volume":"64","author":"Rebouissou","year":"2016","journal-title":"Hepatology"},{"key":"R15-20261111","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1101\/gr.154492.113","article-title":"Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma","volume":"23","author":"Kan","year":"2013","journal-title":"Genome Res"},{"key":"R16-20261111","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/jgh.14903","article-title":"Hepatocellular adenoma in Taiwan: distinct ensemble of male predominance, overweight\/obesity, and inflammatory subtype","volume":"35","author":"Huang","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"R17-20261111","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/path.2169","article-title":"Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations","volume":"212","author":"Audard","year":"2007","journal-title":"J Pathol"},{"key":"R18-20261111","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.humpath.2021.09.009","article-title":"Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification","volume":"119","author":"Torbenson","year":"2022","journal-title":"Hum Pathol"},{"key":"R19-20261111","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1097\/PAS.0b013e3181f31caa","article-title":"Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD\/NASH","volume":"34","author":"Salomao","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R20-20261111","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2017.05.014","article-title":"Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification","volume":"67","author":"Calderaro","year":"2017","journal-title":"J Hepatol"},{"key":"R21-20261111","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for grading activity in chronic hepatitis C","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"R22-20261111","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/PAS.0000000000001716","article-title":"Lymphoepithelioma-like intrahepatic cholangiocarcinoma is a distinct entity with frequent pTERT\/TP53 mutations and comprises 2 subgroups based on Epstein-Barr virus infection","volume":"45","author":"Tsai","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"R23-20261111","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"R24-20261111","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"R25-20261111","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng.3774","article-title":"CIViC is a community knowledge base for expert crowdsourcing the clinical interpretation of variants in cancer","volume":"49","author":"Griffith","year":"2017","journal-title":"Nat Genet"},{"key":"R26-20261111","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/2159-8290.CD-17-0321","article-title":"Accelerating discovery of functional mutant alleles in cancer","volume":"8","author":"Chang","year":"2018","journal-title":"Cancer Discov"},{"key":"R27-20261111","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1126\/science.abn8933","article-title":"Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation","volume":"376","author":"Glassman","year":"2022","journal-title":"Science"},{"key":"R28-20261111","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.immunol.24.021605.090616","article-title":"Structural biology of shared cytokine receptors","volume":"27","author":"Wang","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"R29-20261111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The molecular regulation of Janus kinase (JAK) activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem J"},{"key":"R30-20261111","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.3324\/haematol.2015.138248","article-title":"Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains","volume":"101","author":"Cant\u00e9-Barrett","year":"2016","journal-title":"Haematologica"},{"key":"R31-20261111","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cytogfr.2015.07.010","article-title":"Mutations leading to constitutive active gp130\/JAK1\/STAT3 pathway","volume":"26","author":"Pilati","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"R32-20261111","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"R33-20261111","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/1078-0432.CCR-12-0284","article-title":"Molecular pathways: Jak\/STAT pathway: mutations, inhibitors, and resistance","volume":"19","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Clin Cancer Res"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:00:22Z","timestamp":1794376822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002619","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}